Skip to main content

Table 1 Demographic and clinical background

From: Rivaroxaban for the treatment of cerebral venous thrombosis

Variables

All patients (n = 36)

Warfarin (n = 13)

Rivaroxaban (n = 23)

P value

Age

36

34 ± 11.22

36 ± 11.15

0.510

Sex

36

Male: 1 (7.69%)

Female: 12 (92.31%)

Male: 6 (26.9%)

Female: 17 (73.1%)

0.382

Predisposing factors

 OCP or hormone therapy

7 (19.44%)

3 (23.1%)

4 (17.4%)

0.050

 Predisposing genetic hyper coagulopathy

12 (33.33%)

7 (53.8%)

5 (21.7%)

 Malignancy

4 (11.11%)

0

4 (17.39%)

Cerebral lesion

   

0.708

 Ischemic

25 (69.4%)

10 (76.9%)

15 (65.2%)

 Hemorrhagic

11 (36.6%)

3 (23.1%)

8 (34.8%)

 PHI

8 (81.82%)

3 (100%)

6 (75%)

 PHII

2 (18.18%)

0 (0%)

2 (25%)

  1. OCP Oral Contraceptive Pill, PH Parenchymal Hemorrhage (European Cooperative Acute Stroke Study classification) Quantitative statistics were shown using Mean and Standard Deviations, Mean ± (SD)